首页> 外文OA文献 >FRI0138 Treat to target strategy plus certolizumab in comparison to continued, fixed csdmard plus corticosteroids in patients with rheumatoid arthritis and inadequate response to csdmards (REMISSION BY INTRA-ARTICULAR INJECTION PLUS CERTOLIZUMAB, THE RICE STUDY): a multi-centre randomised controlled trial

【2h】

FRI0138 Treat to target strategy plus certolizumab in comparison to continued, fixed csdmard plus corticosteroids in patients with rheumatoid arthritis and inadequate response to csdmards (REMISSION BY INTRA-ARTICULAR INJECTION PLUS CERTOLIZUMAB, THE RICE STUDY): a multi-centre randomised controlled trial

机译：Fri0138对目标策略加上Certolizumab相比，持续的CSDMARD加上皮质瘤性关节炎患者的皮质类固醇和对CSDMARD的反应不足（内部内注射的缓解，水稻研究）：多中心随机对照试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
R. Mueller; M. Spaeth; C. von Restorff; C. Ackermann; J. von Kempis;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analysis of the Swiss and Austrian patients from the ACT-SURE study [J] . Mueller Ruediger B., Graninger Winfried, Sidiropoulos Paris, Clinical rheumatology . 2017,第10期

机译：与CSDMARDS相比，与CSDMAB单药治疗有活性类风湿性关节炎患者的患者，对CSDMARDS和/或TNF抑制剂的反应不足，中间疾病活动较短，与CSDMAB单药疗法相比学习
2. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial. [J] . Kim H?rslev-Petersen, Merete Lund Hetland, Peter Junker, Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2014,第4期

机译：阿达木单抗增加了甲氨蝶呤和关节内曲安奈德在类风湿关节炎中的靶向治疗策略，从而增加了缓解率，功能和生活质量。 OPERA研究：研究者发起的随机，双盲，平行组，安慰剂对照试验。
3. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial. [J] . Kim H?rslev-Petersen, Merete Lund Hetland, Peter Junker, Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2014,第4期

机译：阿达木单抗增加了甲氨蝶呤和关节内曲安奈德在类风湿关节炎中的靶向治疗策略，从而增加了缓解率，功能和生活质量。 OPERA研究：研究者发起的随机，双盲，平行组，安慰剂对照试验。
4. Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs and New Therapy with Certolizumab Pegol [O] . Ruediger B. Mueller, Michael Spaeth, Cord von Restorff, 2019

机译：靶向治疗策略优于固定csDMARD和皮质类固醇的常规治疗：对常规合成DMARDs反应不佳的RA患者的多中心随机对照试验以及西妥昔单抗Pegol的新疗法
5. Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol [O] . Ruediger Mueller, Michael Spaeth, Cord von Restorff, 2019

机译：用固定的CSDMARD和皮质类固定剂对常规治疗进行治疗对目标策略的优越性：RA患者的多中心随机对照试验，对常规合成DMARD的反应不足，以及与CERTOLIZUMAB PEGOL的新疗法

著录项

引文网络

相似文献

相关主题

期刊订阅